

C Beglinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8631668/publications.pdf>

Version: 2024-02-01

112
papers

8,862
citations

50170

46
h-index

42291

92
g-index

118
all docs

118
docs citations

118
times ranked

8856
citing authors

#	ARTICLE	IF	CITATIONS
1	Erythritol and xylitol differentially impact brain networks involved in appetite regulation in healthy volunteers. <i>Nutritional Neuroscience</i> , 2022, 25, 2344-2358.	1.5	5
2	European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21,533 patients. <i>Gut</i> , 2021, 70, 40-54.	6.1	139
3	Effect of a Chronic Intake of the Natural Sweeteners Xylitol and Erythritol on Glucose Absorption in Humans with Obesity. <i>Nutrients</i> , 2021, 13, 3950.	1.7	6
4	Ghrelin, CCK, GLP-1, and PYY(36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. <i>Physiological Reviews</i> , 2017, 97, 411-463.	13.1	414
5	Green tea effects on cognition, mood and human brain function: A systematic review. <i>Phytomedicine</i> , 2017, 34, 26-37.	2.3	126
6	Characterizing the dynamic interaction among gastric emptying, glucose absorption, and glycemic control in nondiabetic obese adults. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017, 312, R314-R323.	0.9	3
7	Extracellular vesicles in gastrointestinal cancer in conjunction with microbiota: On the border of Kingdoms. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 372-393.	3.3	35
8	Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn's Disease Patients. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 171-179.	0.8	5
9	Effect of L-Tryptophan and L-Leucine on Gut Hormone Secretion, Appetite Feelings and Gastric Emptying Rates in Lean and Non-Diabetic Obese Participants: A Randomized, Double-Blind, Parallel-Group Trial. <i>PLoS ONE</i> , 2016, 11, e0166758.	1.1	29
10	Gut hormone secretion, gastric emptying, and glycemic responses to erythritol and xylitol in lean and obese subjects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E1053-E1061.	1.8	82
11	Functional roles of low calorie sweeteners on gut function. <i>Physiology and Behavior</i> , 2016, 164, 479-481.	1.0	10
12	Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. <i>Endoscopy</i> , 2016, 48, 256-262.	1.0	45
13	Intestinal GLP-1 and satiation: from man to rodents and back. <i>International Journal of Obesity</i> , 2016, 40, 198-205.	1.6	54
14	Mechanisms Regulating Insulin Response to Intra-gastric Glucose in Lean and Non-Diabetic Obese Subjects: A Randomized, Double-Blind, Parallel-Group Trial. <i>PLoS ONE</i> , 2016, 11, e0150803.	1.1	13
15	Lean and obese dietary phenotypes: differences in energy and substrate metabolism and appetite. <i>British Journal of Nutrition</i> , 2015, 114, 1724-1733.	1.2	11
16	English language version of the S3-consensus guidelines on chronic pancreatitis: Definition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2015, 53, 1447-1495.	0.2	125
17	Gastric emptying and disease activity in inflammatory bowel disease. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1234-1242.	1.7	38
18	Dissociable Behavioral, Physiological and Neural Effects of Acute Glucose and Fructose Ingestion: A Pilot Study. <i>PLoS ONE</i> , 2015, 10, e0130280.	1.1	36

#	ARTICLE	IF	CITATIONS
19	Serum Levels of Human MIC-1/GDF15 Vary in a Diurnal Pattern, Do Not Display a Profile Suggestive of a Satiety Factor and Are Related to BMI. <i>PLoS ONE</i> , 2015, 10, e0133362.	1.1	66
20	The role and utility of faecal markers in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 23-36.	1.4	140
21	Exercise-induced Chest Pain: An Atypical Manifestation of Eosinophilic Esophagitis. <i>American Journal of Medicine</i> , 2015, 128, 196-199.	0.6	16
22	Fecal Calprotectin and the Clinical Activity Index Are Both Useful to Monitor Medical Treatment in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 485-491.	1.1	24
23	Sleep Disruption and Daytime Sleepiness Correlating with Disease Severity and Insulin Resistance in Non-Alcoholic Fatty Liver Disease: A Comparison with Healthy Controls. <i>PLoS ONE</i> , 2015, 10, e0143293.	1.1	66
24	Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87488.	1.1	84
25	Effect of a test meal on meal responses of satiety hormones and their association to insulin resistance in obese adolescents. <i>Obesity</i> , 2014, 22, 2047-2052.	1.5	16
26	Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men. <i>American Journal of Clinical Nutrition</i> , 2014, 100, 514-523.	2.2	41
27	Gut Sweet Taste Receptors and Their Role in Metabolism. <i>Frontiers of Hormone Research</i> , 2014, 42, 123-133.	1.0	17
28	Gastric and intestinal satiety in obese and normal weight healthy people. <i>Physiology and Behavior</i> , 2014, 129, 265-271.	1.0	78
29	Faecal calprotectin testing – the need for better standardization. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 583-584.	8.2	6
30	The use of fecal calprotectin as a biomarker in gastrointestinal disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 197-210.	1.4	82
31	Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1392-1397.	0.6	40
32	Topical therapy is underused in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 56-63.	0.6	52
33	The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1427-1437.	0.6	31
34	Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 4994.	1.4	24
35	Effects of Chenodeoxycholic Acid on the Secretion of Gut Peptides and Fibroblast Growth Factors in Healthy Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3351-3358.	1.8	41
36	Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. <i>Clinica Chimica Acta</i> , 2013, 416, 41-47.	0.5	29

#	ARTICLE	IF	CITATIONS
37	Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 332-341.	0.9	240
38	Bile acids and gut peptide secretion after bariatric surgery: A 1-year prospective randomized pilot trial. <i>Obesity</i> , 2013, 21, E666-8.	1.5	162
39	DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: Secretion of gastrointestinal hormones and eating control1. <i>Journal of Animal Science</i> , 2013, 91, 1963-1973.	0.2	46
40	The role of the stomach in the control of appetite and the secretion of satiation peptides. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 302, E666-E673.	1.8	41
41	Monitoring inflammatory bowel disease activity: Clinical activity is judged to be more relevant than endoscopic severity or biomarkers. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 412-418.	0.6	54
42	Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. <i>Endocrine</i> , 2012, 42, 366-374.	1.1	18
43	Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. <i>BMC Gastroenterology</i> , 2012, 12, 5.	0.8	71
44	Metabolic and Hormonal Changes After Laparoscopic Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: a Randomized, Prospective Trial. <i>Obesity Surgery</i> , 2012, 22, 740-748.	1.1	425
45	Faecal calprotectin - a useful tool in the management of inflammatory bowel disease. <i>Swiss Medical Weekly</i> , 2012, 142, w13557.	0.8	46
46	Nutrient sensing in the gut: interactions between chemosensory cells, visceral afferents and the secretion of satiation peptides. <i>Physiology and Behavior</i> , 2011, 105, 62-70.	1.0	80
47	The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). <i>Clinical Nutrition</i> , 2011, 30, 524-532.	2.3	147
48	Metabolic surgery—principles and current concepts. <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 949-972.	0.8	30
49	Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides. <i>British Journal of Nutrition</i> , 2011, 105, 1320-1328.	1.2	202
50	The role of the gut sweet taste receptor in regulating GLP-1, PYY, and CCK release in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 301, E317-E325.	1.8	159
51	Zinc Salts Provide a Novel, Prolonged and Rapid Inhibition of Gastric Acid Secretion. <i>American Journal of Gastroenterology</i> , 2011, 106, 62-70.	0.2	17
52	Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. <i>American Journal of Clinical Nutrition</i> , 2010, 92, 810-817.	2.2	81
53	Role of Fat Hydrolysis in Regulating Glucagon-Like Peptide-1 Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 879-886.	1.8	122
54	Diagnosis of Chronic Pancreatitis. <i>Digestive Diseases</i> , 2010, 28, 359-363.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Therapeutic Potential of Gut Peptides. Forum of Nutrition, 2010, 63, 54-63.	3.7	7
56	Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI. American Journal of Gastroenterology, 2010, 105, 162-169.	0.2	481
57	Mechanisms of gastric emptying disturbances in chronic and acute inflammation of the distal gastrointestinal tract. American Journal of Physiology - Renal Physiology, 2009, 297, G861-G868.	1.6	45
58	Effect of Food on the Pharmacokinetics and Pharmacodynamics of an Oral Ghrelin Agonist (ARDâ€07) in Healthy Subjects. Journal of Clinical Pharmacology, 2009, 49, 553-559.	1.0	10
59	Ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 1851-1858.	0.9	275
60	Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects. Clinical Pharmacology and Therapeutics, 2009, 86, 644-650.	2.3	41
61	CCK, ghrelin, and PYY responses in individuals with binge eating disorder before and after a cognitive behavioral treatment (CBT). Physiology and Behavior, 2009, 97, 14-20.	1.0	26
62	Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects. Clinical Pharmacology and Therapeutics, 2008, 84, 468-474.	2.3	46
63	Ethics Related to Drug Therapy in the Elderly. Digestive Diseases, 2008, 26, 28-31.	0.8	13
64	Regulation of Fat-Stimulated Neurotensin Secretion in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1964-1970.	1.8	23
65	Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R1391-R1399.	0.9	73
66	Effect of Intravenous Esomeprazole 40 mg and Pantoprazole 40 mg on Intragastric pH in Healthy Subjects. Arzneimittelforschung, 2007, 57, 645-658.	0.5	0
67	Effect of gastric distension prior to eating on food intake and feelings of satiety in humans. Physiology and Behavior, 2006, 87, 903-910.	1.0	69
68	Gastrointestinal satiety signals in humans â€” Physiologic roles for GLP-1 and PYY ?. Physiology and Behavior, 2006, 89, 460-464.	1.0	95
69	Are higher doses of rifaximin more effective for the treatment of small-intestinal bacterial overgrowth?. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 22-23.	1.7	0
70	Gastrin-Releasing Peptide. , 2006, , 1047-1055.		2
71	Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologists Perspective. Current Topics in Medicinal Chemistry, 2005, 5, 449-464.	1.0	25
72	Role of pantoprazole in the treatment of gastro-oesophageal reflux disease. Expert Opinion on Pharmacotherapy, 2005, 6, 93-104.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Effect of Peptide YY3â€“36 on Food Intake in Humans. <i>Gastroenterology</i> , 2005, 129, 1430-1436.	0.6	313
74	Fat in the intestine as a regulator of appetiteâ€”role of CCK. <i>Physiology and Behavior</i> , 2004, 83, 617-621.	1.0	112
75	High prevalence of <i>cagA</i> and <i>vacA</i> seropositivity in asymptomatic Bangladeshi children with <i>Helicobacter pylori</i> infection. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2004, 93, 1432-1436.	0.7	9
76	New Molecular Targets for Treatment of Peptic Ulcer Disease. <i>Drugs</i> , 2003, 63, 1785-1797.	4.9	32
77	Role of thyrotrophin releasing hormone and corticotrophin releasing factor in stress related alterations of gastrointestinal motor function. <i>Gut</i> , 2002, 51, i45-i49.	6.1	14
78	Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome. <i>International Journal of Clinical Practice</i> , 2002, 56, 47-51.	0.8	17
79	Overview. Cholecystokinin and eating. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 587-8.	2.3	11
80	Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit. <i>Gastroenterology</i> , 2001, 120, 361-368.	0.6	33
81	Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2001, 280, R1149-R1154.	0.9	161
82	A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7â€“36) Amide on Ad Libitum Energy Intake in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4382-4389.	1.8	468
83	Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist. <i>Gut</i> , 2001, 49, 23-28.	6.1	51
84	Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-?. , 2000, 85, 720-725.		86
85	Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response. <i>European Journal of Immunology</i> , 2000, 30, 2593-2603.	1.6	47
86	Interaction between CCK and a preload on reduction of food intake is mediated by CCK-A receptors in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2000, 279, R189-R195.	0.9	61
87	The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans. <i>Gut</i> , 2000, 46, 689-694.	6.1	163
88	Gastrin Releasing Peptide-Preferring Bombesin Receptors Mediate Growth of Human Renal Cell Carcinoma. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1409-1418.	3.0	44
89	Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999, 277, R1718-R1724.	0.9	58
90	Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999, 276, R1541-R1544.	0.9	247

#	ARTICLE	IF	CITATIONS
91	Somatostatin and Octreotide: Physiological Background and Pharmacological Application. <i>Digestion</i> , 1999, 60, 2-8.	1.2	25
92	Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans. <i>European Journal of Clinical Investigation</i> , 1999, 29, 153-159.	1.7	23
93	Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 413-419.	2.3	6
94	Glucagon-like peptide-1: a potent regulator of food intake in humans. <i>Gut</i> , 1999, 44, 81-86.	6.1	497
95	Hemodynamic effects of the somatostatin analog lanreotide in humans: Placebo-controlled, cross-over dose-ranging echo-doppler study. <i>Hepatology</i> , 1998, 27, 920-925.	3.6	28
96	Pancreatic bicarbonate response to intraduodenal tryptophan in dogs. <i>International Journal of Gastrointestinal Cancer</i> , 1998, 23, 31-39.	0.4	8
97	Hydrolysis of dietary fat by pancreatic lipase stimulates cholecystokinin release. <i>Gastroenterology</i> , 1998, 114, 123-129.	0.6	80
98	Circulating somatostatin-28 is not a physiologic regulator of gastric acid production in man. <i>European Journal of Clinical Investigation</i> , 1994, 24, 50-56.	1.7	79
99	Effects of BIM26226, a potent and specific bombesin receptor antagonist, on amylase release and binding of bombesin-like peptides to AR4-2J cells. <i>Regulatory Peptides</i> , 1994, 53, 165-173.	1.9	20
100	Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. <i>Regulatory Peptides</i> , 1994, 51, 151-159.	1.9	315
101	Therapeutic effects of loxiglumide, a cholecystokinin antagonist, on chronic constipation in elderly patients: a prospective, randomized, double-blind, controlled trial. <i>Neurogastroenterology and Motility</i> , 1993, 5, 129-135.	1.6	11
102	Role of circulating cholecystokinin in control of fat-induced inhibition of food intake in humans. <i>Gastroenterology</i> , 1992, 102, 1654-1659.	0.6	69
103	A physiological role for cholecystokinin as a regulator of gastrin secretion. <i>Gastroenterology</i> , 1992, 103, 490-495.	0.6	40
104	Evidence for hormonal inhibition of exocrine pancreatic function by somatostatin 28 in humans. <i>Gastroenterology</i> , 1992, 103, 240-247.	0.6	23
105	Intracolonic bioavailability of human calcitonin in man. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 527-531.	0.8	20
106	Postprandial control of gallbladder contraction and exocrine pancreatic secretion in man. <i>European Journal of Clinical Investigation</i> , 1992, 22, 827-834.	1.7	46
107	Human gastrin-releasing peptide: biological potency in humans. <i>Regulatory Peptides</i> , 1991, 36, 423-433.	1.9	28
108	Effect of loxiglumide, a cholecystokinin antagonist, on pancreatic polypeptide release in humans. <i>Gastroenterology</i> , 1990, 99, 1757-1762.	0.6	46

#	ARTICLE	IF	CITATIONS
109	Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.. Journal of Clinical Investigation, 1990, 85, 640-646.	3.9	127
110	ROLE OF CHOLECYSTOKININ IN REGULATION OF GASTROINTESTINAL MOTOR FUNCTIONS. Lancet, The, 1989, 334, 12-15.	6.3	208
111	To extract or not to extract in secretin radioimmunoassay?. International Journal of Gastrointestinal Cancer, 1988, 3, 357-366.	0.4	2
112	Effect of calcitonin and calcitonin gene-related peptide on pancreatic functions in man.. Gut, 1988, 29, 243-248.	6.1	22